Rigel Announces Publication of Data on REZLIDHIA® (Olutasidenib) in Post-Venetoclax Patients with Mutant IDH1 AML in Leukemia & Lymphoma
Stock Information for Rigel Pharmaceuticals Inc.
Loading
Please wait while we load your information from QuoteMedia.